{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:27:56Z","timestamp":1789140476226,"version":"build-2803163510"},"reference-count":76,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016114","name":"Zhejiang Medical Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016114","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>\n                    <jats:italic>Helicobacter pylori<\/jats:italic>\n                    (\n                    <jats:italic>H. pylori<\/jats:italic>\n                    ) infection remains highly prevalent worldwide and is strongly associated with chronic gastritis, peptic ulcer disease, and an elevated risk of gastric cancer. In pediatric clinical practice, eradication therapy is challenged by rising antibiotic resistance, inadequate acid suppression, and poor adherence to complex multidrug regimens. Potassium-competitive acid blockers (P-CABs) represent a newer class of antisecretory agents that competitively and reversibly inhibit gastric H\n                    <jats:sup>+<\/jats:sup>\n                    \/K\n                    <jats:sup>+<\/jats:sup>\n                    -ATPase, resulting in a more rapid onset and more sustained control of intragastric pH compared with conventional proton pump inhibitors (PPIs). P-CABs offer greater flexibility in dosing timing relative to meals in children, with substantial potential to simplify treatment regimens and improve\n                    <jats:italic>H. pylori<\/jats:italic>\n                    eradication rates in the pediatric population. This narrative review summarizes the pharmacologic rationale for using P-CABs in pediatric\n                    <jats:italic>H. pylori<\/jats:italic>\n                    eradication, synthesizes current clinical evidence\u2014derived mainly from Japanese observational studies of vonoprazan (VPZ)\u2014and discusses key issues regarding resistance, tolerability, and practical clinical application. Published pediatric studies, predominantly involving adolescents and older pediatric cohorts, suggest that VPZ-based regimens may achieve favorable eradication rates, while short-term tolerability appears broadly similar to that of PPI-based therapies in the available comparative data. However, the existing evidence is limited by small sample sizes, narrow geographic scope, and marked heterogeneity in study design, antibiotic backbones, and resistance patterns, which preclude direct cross-study comparisons. Data supporting other P-CABs in pediatric populations remain very scarce. Future research should prioritize pediatric pharmacokinetic\/pharmacodynamic studies to optimize weight- and age-based dosing, conduct resistance-stratified comparative trials, and perform cost-effectiveness analyses. Until more robust pediatric evidence becomes available, P-CAB-based regimens may be considered a viable option in selected clinical scenarios, while clinicians should exercise caution when extrapolating adult data and remain vigilant toward local antibiotic resistance epidemiology.\n                  <\/jats:p>","DOI":"10.3389\/fcimb.2026.1810850","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:56:32Z","timestamp":1778651792000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Potassium-competitive acid blockers for Helicobacter pylori eradication in pediatrics: a narrative review of pharmacologic rationale, clinical evidence, and practical considerations"],"prefix":"10.3389","volume":"16","author":[{"given":"Bingyan","family":"Gu","sequence":"first","affiliation":[{"name":"The First School of Clinical Medicine, Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Le","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifang","family":"Cai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70021","article-title":"Global prevalence of helicobacter pylori infection-associated gastric preneoplastic lesions in pediatric patients: A systematic review and meta-analysis","volume":"30","author":"Abdun","year":"2025","journal-title":"Helicobacter"},{"key":"B2","first-page":"88","article-title":"High percentage of clarithromycin and metronidazole resistance in helicobacter pylori clinical isolates obtained from Spanish children","volume":"22","author":"Agudo","year":"2009","journal-title":"Rev. Esp Quimioter: Publ Soc Esp Quimioter"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3703","DOI":"10.1128\/jcm.00144-10","article-title":"High prevalence of clarithromycin-resistant helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain","volume":"48","author":"Agudo","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/00494755251367099","article-title":"Helicobacter pylori in children: Risk factors and diagnosis of infection in the family members","volume":"55","author":"Aguilera-Matos","year":"2025","journal-title":"Trop. Doct"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0318315","article-title":"Effectiveness of first line therapy for helicobacter pylori infection in children and adolescents: A multicenter study in the United Arab Emirates","volume":"20","author":"Al Atrash","year":"2025","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.pharmthera.2005.05.005","article-title":"Potassium-competitive acid blockade: A new therapeutic strategy in acid-related diseases","volume":"108","author":"Andersson","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/0016-5085(95)90689-4","article-title":"Double-blind trial of omeprazole and amoxicillin to cure helicobacter pylori infection in patients with duodenal ulcers","volume":"108","author":"Bayerd\u00f6rffer","year":"1995","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13142","article-title":"Efficacy of bismuth therapy in eradicating helicobacter pylori in children-data from the RENIHp registry","volume":"29","author":"Botija","year":"2024","journal-title":"Helicobacter"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001870","article-title":"Role of vonoprazan-amoxicillin dual therapy in pediatric refractory helicobacter pylori infection in children: Early experience from a single-center case series","volume":"12","author":"Cardenas Fernandez","year":"2025","journal-title":"ACG Case Rep. J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5152\/tjg.2016.0278","article-title":"Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: Impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance","volume":"28","author":"\u00c7ekin","year":"2017","journal-title":"Turk J. Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13149","article-title":"Efficacy of bismuth quadruple therapy in the treatment of helicobacter pylori-infected peptic ulcer children in Vietnam","volume":"29","author":"Do","year":"2024","journal-title":"Helicobacter"},{"key":"B12","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/jac\/dkr016","article-title":"Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in streptococcus pneumoniae","volume":"66","author":"Drago","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13057","article-title":"Primary antibiotic resistance of helicobacter pylori in India over the past two decades: A systematic review","volume":"29","author":"Dutta","year":"2024","journal-title":"Helicobacter"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00431-018-3282-z","article-title":"Efficacy of lactobacillus-supplemented triple therapy for helicobacter pylori infection in children: A meta-analysis of randomized controlled trials","volume":"178","author":"Fang","year":"2019","journal-title":"Eur. J. Pediatr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","article-title":"Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-na\u00efve cohort of junior high school students in Japan","volume":"55","author":"Gotoda","year":"2020","journal-title":"J. Gastroenterol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00535-010-0220-x","article-title":"Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: Studies from the United States","volume":"45","author":"Graham","year":"2010","journal-title":"J. Gastroenterol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3164\/jcbn.20-51","article-title":"Nutrients and probiotics: Current trends in their use to eradicate helicobacter pylori","volume":"67","author":"Handa","year":"2020","journal-title":"J. Clin. Biochem. Nutr."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000000685","article-title":"Probiotics for standard triple helicobacter pylori eradication: A randomized, double-blind, placebo-controlled trial","volume":"94","author":"Hauser","year":"2015","journal-title":"Med. (Baltimore)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1523-5378.2007.00560.x","article-title":"Methods to detect helicobacter pylori: From culture to molecular biology","volume":"12","author":"Hirschl","year":"2007","journal-title":"Helicobacter"},{"key":"B20","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/jpn3.12314","article-title":"Updated joint ESPGHAN\/NASPGHAN guidelines for management of helicobacter pylori infection in children and adolescents (2023)","volume":"79","author":"Homan","year":"2024","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70063","article-title":"Helicobacter pylori infection in children versus adults, differences in management guidelines: Risks and benefits of treatment in childhood","volume":"30","author":"Homan","year":"2025","journal-title":"Helicobacter"},{"key":"B22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of helicobacter pylori in the Asia-pacific region between 1990 and 2022: An updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1111\/jgh.15572","article-title":"Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for helicobacter pylori eradication","volume":"36","author":"Horii","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12970","article-title":"Eradication rates of helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China","volume":"28","author":"Hu","year":"2023","journal-title":"Helicobacter"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-026-02379-4","article-title":"Guidelines for the management of helicobacter pylori infection in Japan: 2024 revised edition","author":"Isomoto","year":"2026","journal-title":"J. Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomized clinical trial: Safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol. Ther."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12383","article-title":"Eradication rate of helicobacter pylori infection is directly influenced by adherence to therapy in children","volume":"22","author":"K","year":"2017","journal-title":"Helicobacter"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol. Ther."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12696","article-title":"Helicobacter pylori test-and-treat strategy for second-year junior high school students aimed at the prevention of gastric cancer in Takatsuki city","volume":"25","author":"Kaji","year":"2020","journal-title":"Helicobacter"},{"key":"B30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/00365521.2016.1250157","article-title":"Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line helicobacter pylori eradication","volume":"52","author":"Kajihara","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1216433","article-title":"Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line helicobacter pylori agents","volume":"14","author":"Kakiuchi","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00535-019-01559-9","article-title":"A helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in saga prefecture: A preliminary report","volume":"54","author":"Kakiuchi","year":"2019","journal-title":"J. Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12776","article-title":"Gastrointestinal adverse reactions reduce the success rate of helicobacter pylori eradication therapy: A multicenter prospective cohort study","volume":"26","author":"Kakiuchi","year":"2021","journal-title":"Helicobacter"},{"key":"B34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00535-022-01942-z","article-title":"Efficacy and safety of vonoprazan-based regimen for helicobacter pylori eradication therapy in Japanese adolescents: A prospective multicenter study","volume":"58","author":"Kakiuchi","year":"2023","journal-title":"J. Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/jpn3.70254","article-title":"Gastric ghrelin is reduced in children with helicobacter pylori gastritis compared to children without helicobacter pylori","volume":"82","author":"Krauthammer","year":"2026","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s10120-017-0688-7","article-title":"The administrative project of helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer","volume":"20","author":"Kusano","year":"2017","journal-title":"Gastric Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s00535-017-1406-2","article-title":"Safety of first-line triple therapy with a potassium-competitive acid blocker for helicobacter pylori eradication in children","volume":"53","author":"Kusano","year":"2018","journal-title":"J. Gastroenterol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1648047","article-title":"High dose ilaprazole\/amoxicillin as first-line regimen for helicobacter pylori infection in Korea","volume":"2016","author":"Kwack","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"key":"B39","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s15010-022-01948-y","article-title":"Management of helicobacter pylori infection in pediatric patients in Europe: Results from the EuroPedHp registry","volume":"51","author":"Le Thi","year":"2023","journal-title":"Infection"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13134","article-title":"Factors associated with decision to treat or not to treat helicobacter pylori infection in children: Data from the EuroPedHp registry","volume":"29","author":"Le Thi","year":"2024","journal-title":"Helicobacter"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12373","article-title":"Antibiotic resistance of helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years","volume":"22","author":"Li","year":"2017","journal-title":"Helicobacter"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1111\/cas.70112","article-title":"Gastric signet ring cell carcinoma in a helicobacter pylori-positive 10-year-old boy: A case report and literature review","volume":"116","author":"Li","year":"2025","journal-title":"Cancer Sci."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003924","article-title":"Cost-effectiveness of first-line regimens for helicobacter pylori infection in the United States","author":"Liu","year":"2026","journal-title":"Am. J. Gastroenterol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12940","article-title":"Quadruple therapy with vonoprazan 20\u2009mg daily as a first-line treatment for helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial","volume":"28","author":"Lu","year":"2023","journal-title":"Helicobacter"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.3748\/wjg.v28.i28.3682","article-title":"Gastric mucosal precancerous lesions in helicobacter pylori-infected pediatric patients in central China: A single-center, retrospective investigation","volume":"28","author":"M","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2544886","article-title":"Research progress of potassium-competitive acid blockers in the treatment of helicobacter pylori","volume":"57","author":"Ma","year":"2025","journal-title":"Ann. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of helicobacter pylori infection: The maastricht III consensus report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of helicobacter pylori infection: The maastricht VI\/Florence consensus report","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.71238","article-title":"Global profile of drug resistance related to helicobacter pylori infection in children: A systematic review and meta-analysis","volume":"8","author":"Menbari","year":"2025","journal-title":"Health Sci. Rep."},{"key":"B50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/ped.13038","article-title":"Nationwide survey of helicobacter pylori treatment for children and adolescents in Japan","volume":"59","author":"Okuda","year":"2017","journal-title":"Pediatr. Int. Off. J. Jpn. Pediatr. Soc"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70106","article-title":"Tegoprazan-based triple therapy for helicobacter pylori eradication: A phase III multicenter randomized clinical trial","volume":"31","author":"Park","year":"2026","journal-title":"Helicobacter"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1053\/j.gastro.2024.06.038","article-title":"AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: Expert review","volume":"167","author":"Patel","year":"2024","journal-title":"Gastroenterology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jpn3.12421","article-title":"Factors associated with Helicobacter pylori antimicrobial resistance in a US pediatric cohort","volume":"80","author":"Riaz","year":"2025","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B54","doi-asserted-by":"publisher","first-page":"787","DOI":"10.14309\/ajg.0000000000003084","article-title":"Comparative efficacy and safety of potassium-competitive acid blocker-based dual, triple, and quadruple regimens for first-line helicobacter pylori infection treatment: A systematic review and network meta-analysis","volume":"120","author":"Rokkas","year":"2025","journal-title":"Am. J. Gastroenterol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70083","article-title":"Vonoprazan-based triple therapy versus esomeprazole-based triple therapy for H. pylori eradication in adolescents (VONTAPE): A randomized, double-blind controlled trial","volume":"30","author":"Sa","year":"2025","journal-title":"Helicobacter"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1111\/jgh.70067","article-title":"Helicobacter pylori screening and eradication in junior high school students in yokosuka, Japan: Prevalence, eradication rates, and challenges","volume":"40","author":"Saito","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12916-024-03816-y","article-title":"Global prevalence of helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: A systematic review and meta-analysis","volume":"22","author":"Salahi-Niri","year":"2024","journal-title":"BMC Med."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13349","article-title":"Cost-effectiveness analysis and effectiveness of pharmacist-managed outpatient clinics in helicobacter pylori eradication therapy","volume":"73","author":"Seko","year":"2019","journal-title":"Int. J. Clin. Pract."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00228-025-03912-9","article-title":"Optimizing acid-related disease management: Insights into potassium-competitive acid blockers and proton pump inhibitors","volume":"81","author":"Shang","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40265-023-01991-5","article-title":"Vonoprazan: A review in helicobacter pylori infection","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"B61","doi-asserted-by":"publisher","first-page":"17754","DOI":"10.1038\/s41598-022-21661-y","article-title":"Alarming antibiotics resistance of helicobacter pylori from children in southeast China over 6 years","volume":"12","author":"Shu","year":"2022","journal-title":"Sci. Rep."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1097\/cm9.0000000000003437","article-title":"Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study","volume":"138","author":"Song","year":"2025","journal-title":"Chin. Med. J. (Engl)"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/hel.70103","article-title":"An open-label randomized controlled trial comparing the efficacy and safety of a 7-day triple therapy with bismuth versus 14-day standard triple therapy for helicobacter pylori eradication in children and adolescents","volume":"31","author":"\u0160terbenc","year":"2026","journal-title":"Helicobacter"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","article-title":"Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line helicobacter pylori treatment: A multicenter randomized trial in Japan","volume":"69","author":"Suzuki","year":"2020","journal-title":"Gut"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107320","article-title":"The efficacy of keverprazan-based quadruple therapy for helicobacter pylori eradication: A phase III, randomized, double-blind, multicenter trial","volume":"64","author":"Tan","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B66","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12887-025-05588-7","article-title":"Prevalence, associated factors, and clinical outcomes of helicobacter pylori infection in pediatric populations in a war-torn urban environment in eastern democratic republic of Congo: A mixed methods study","volume":"25","author":"Tibasima","year":"2025","journal-title":"BMC Pediatr."},{"key":"B67","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41575-025-01166-5","article-title":"Potassium-competitive acid blockers for the management of gastroesophageal reflux disease","volume":"23","author":"Visaggi","year":"2026","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1111\/hel.13139","article-title":"Tracking the helicobacter pylori epidemic in adults and children in China","volume":"29","author":"Wang","year":"2024","journal-title":"Helicobacter"},{"key":"B69","doi-asserted-by":"publisher","first-page":"96409","DOI":"10.18632\/oncotarget.21633","article-title":"Probiotics in 14- day triple therapy for asian pediatric patients with helicobacter pylori infection: A network meta-analysis","volume":"8","author":"Wen","year":"2017","journal-title":"Oncotarget"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i39.111380","article-title":"Sequential changes of antibiotic resistances of helicobacter pylori in Taiwan from 2019 to 2024","volume":"31","author":"Wu","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00535-024-02114-x","article-title":"Global H. pylori recurrence, recrudescence, and re-infection status after successful eradication in pediatric patients: A systematic review and meta-analysis","volume":"59","author":"Xu","year":"2024","journal-title":"J. Gastroenterol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cgh.2014.10.036","article-title":"High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection","volume":"13","author":"Yang","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12713","article-title":"Changes in the human gut microbiota composition caused by helicobacter pylori eradication therapy: A systematic review and meta-analysis","volume":"25","author":"Ye","year":"2020","journal-title":"Helicobacter"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00312-25","article-title":"Correlation between helicobacter pylori infection and severity of gastritis in children","volume":"13","author":"Zheng","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.625586","article-title":"The effects of helicobacter pylori infection on microbiota associated with gastric mucosa and immune factors in children","volume":"12","author":"Zheng","year":"2021","journal-title":"Front. Immunol."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12809","article-title":"Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for helicobacter pylori eradication in Chinese children","volume":"26","author":"Zhou","year":"2021","journal-title":"Helicobacter"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1810850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:56:33Z","timestamp":1778651793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1810850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":76,"alternative-id":["10.3389\/fcimb.2026.1810850"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1810850","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1810850"}}